Replicel Life Sciences Stock Performance
| RP Stock | CAD 0.01 0.00 0.00% |
The company holds a Beta of 1.55, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, RepliCel Life will likely underperform. At this point, RepliCel Life Sciences has a negative expected return of -0.78%. Please make sure to check RepliCel Life's jensen alpha and kurtosis , to decide if RepliCel Life Sciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days RepliCel Life Sciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
Last Split Factor 1:10 | Dividend Date 2016-08-10 | Last Split Date 2016-08-10 |
1 | RepliCel Life Sciences Urges Online Access for Shareholders - TipRanks | 12/04/2024 |
| Begin Period Cash Flow | 413 K |
RepliCel |
RepliCel Life Relative Risk vs. Return Landscape
If you would invest 5.50 in RepliCel Life Sciences on September 19, 2024 and sell it today you would lose (4.50) from holding RepliCel Life Sciences or give up 81.82% of portfolio value over 90 days. RepliCel Life Sciences is currently does not generate positive expected returns and assumes 21.5256% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than RepliCel, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
RepliCel Life Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for RepliCel Life's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as RepliCel Life Sciences, and traders can use it to determine the average amount a RepliCel Life's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0362
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RP |
Estimated Market Risk
| 21.53 actual daily | 96 96% of assets are less volatile |
Expected Return
| -0.78 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average RepliCel Life is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of RepliCel Life by adding RepliCel Life to a well-diversified portfolio.
RepliCel Life Fundamentals Growth
RepliCel Stock prices reflect investors' perceptions of the future prospects and financial health of RepliCel Life, and RepliCel Life fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on RepliCel Stock performance.
| Return On Asset | -1.53 | ||||
| Profit Margin | 2.16 % | ||||
| Operating Margin | (0.74) % | ||||
| Current Valuation | 744.26 K | ||||
| Shares Outstanding | 73.58 M | ||||
| Price To Earning | (1.05) X | ||||
| Price To Sales | 2.08 X | ||||
| Revenue | 353.74 K | ||||
| Gross Profit | 353.74 K | ||||
| EBITDA | (1.38 M) | ||||
| Net Income | (311.73 K) | ||||
| Cash And Equivalents | 1.16 M | ||||
| Cash Per Share | 0.04 X | ||||
| Total Debt | 813.19 K | ||||
| Current Ratio | 2.09 X | ||||
| Book Value Per Share | (0.07) X | ||||
| Cash Flow From Operations | (1.41 M) | ||||
| Earnings Per Share | (0.02) X | ||||
| Market Capitalization | 735.78 K | ||||
| Total Asset | 287.79 K | ||||
| Retained Earnings | (43.29 M) | ||||
| Working Capital | (1.44 M) | ||||
About RepliCel Life Performance
Evaluating RepliCel Life's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if RepliCel Life has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if RepliCel Life has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.08) | (1.14) | |
| Return On Capital Employed | 0.90 | 0.95 | |
| Return On Assets | (1.08) | (1.14) | |
| Return On Equity | 0.07 | 0.07 |
Things to note about RepliCel Life Sciences performance evaluation
Checking the ongoing alerts about RepliCel Life for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for RepliCel Life Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| RepliCel Life generated a negative expected return over the last 90 days | |
| RepliCel Life has high historical volatility and very poor performance | |
| RepliCel Life has some characteristics of a very speculative penny stock | |
| RepliCel Life has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 353.74 K. Net Loss for the year was (311.73 K) with profit before overhead, payroll, taxes, and interest of 353.74 K. | |
| RepliCel Life Sciences currently holds about 1.16 M in cash with (1.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 59.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: RepliCel Life Sciences Urges Online Access for Shareholders - TipRanks |
- Analyzing RepliCel Life's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether RepliCel Life's stock is overvalued or undervalued compared to its peers.
- Examining RepliCel Life's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating RepliCel Life's management team can have a significant impact on its success or failure. Reviewing the track record and experience of RepliCel Life's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of RepliCel Life's stock. These opinions can provide insight into RepliCel Life's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for RepliCel Stock Analysis
When running RepliCel Life's price analysis, check to measure RepliCel Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RepliCel Life is operating at the current time. Most of RepliCel Life's value examination focuses on studying past and present price action to predict the probability of RepliCel Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RepliCel Life's price. Additionally, you may evaluate how the addition of RepliCel Life to your portfolios can decrease your overall portfolio volatility.